Efficacy of antimicrobials or placebo compared to amoxicillin-clavulanate in children with acute otitis media: a systematic review.

Abstract

BACKGROUND:

Acute otitis media (AOM) is the inflammation of the middle ear. It constitutes one of the most frequent infections which affects children and usually occurs between 6 to 24 months of age. AOM can emerge due to viruses and/or bacteria. The aim of the current systematic review is to assess in children between 6 months and 12 years of age with AOM, the efficacy of any antimicrobial agent or placebo compared with amoxicillinclavulanate, to measure the resolution of AOM or symptoms.

METHODS:

The medical databases PubMed (MEDLINE) and Web of Science were used. Data extraction and analysis were performed by two independent reviewers. Eligibility criteria were set, and only randomised control trials (RCTs) were included. Critical appraisal of the eligible studies was performed. Pooled analysis was conducted using the Review Manager v. 5.4.1 software (RevMan).

RESULTS:

Twelve RCTs were totally included. Three (25.0%) RCTs studied the impact of azithromycin, two (16.7%) investigated the impact of cefdinir, two (16.7%) investigated placebo, three (25.0%) studied quinolones, one (8.3%) investigated cefaclor and one (8.3%) studied penicillin V, compared to amoxicillin-clavulanate. In five (41.7%) RCTs, amoxicillin-clavulanate proved to be superior to azithromycin, cefdinir, placebo, cefaclor and penicillin V, while in seven (58.3%) RCTs its efficacy was comparable with other antimicrobials or placebo. The rates of AOM relapse after treatment with amoxicillin-clavulanate were comparable to those of other antimicrobials or placebo. However, amoxicillin-clavulanate was more effective in eradicating Streptococcus pneumoniae from the culture, when compared to cefdinir. The results of the meta-analysis were not evaluated due to substantial heterogeneity between studies.

CONCLUSIONS:

Amoxicillin-clavulanate should be the treatment of choice for children between 6 months and 12 years of age with AOM.

• Authors: Katerina Tsergouli, Nikolaos Karampatakis, Theodoros Karampatakis
• Journal: The Turkish journal of pediatrics (Turk J Pediatr) Vol. 65 Issue 3 Pg. 351-361 ( 2023) ISSN: 2791-6421 [Electronic] Turkey
• PMID: 37395955 (Publication Type: Journal Article, Review, Systematic Review)

Chemical References

• Amoxicillin
• Amoxicillin-Potassium Clavulanate Combination
• Anti-Bacterial Agents
• Anti-Infective Agents
• Azithromycin
• Cefaclor
• Cefdinir
• Penicillin V

Topics

• Child
• Humans
• Infant
• Acute Disease
• Amoxicillin (therapeutic use)
• Amoxicillin-Potassium Clavulanate Combination (therapeutic use)
• Anti-Bacterial Agents (therapeutic use)
• Anti-Infective Agents (therapeutic use)
• Azithromycin (therapeutic use)
• Cefaclor (therapeutic use)
• Cefdinir (therapeutic use)
• Otitis Media (drug therapy, microbiology)
• Penicillin V (therapeutic use)
• Treatment Outcome